Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

CBL-0102 receives U.S. orphan drug designation for hepatocellular carcinoma

Oct. 4, 2012

Servier and EOS conclude collaboration and license agreement for E-3810

Oct. 4, 2012

Curis begins phase I trial of oral formulation of CUDC-101 in solid tumors

Oct. 4, 2012

Spanish researchers disclose new immunogenic compositions

Oct. 4, 2012

Astex begins phase II trial of SGI-110 in platinum-resistant recurrent ovarian cancer

Oct. 4, 2012

Phase III Abraxane trial meets primary endpoint

Oct. 4, 2012

New B-raf inhibitors presented by Array BioPharma and Genentech

Oct. 4, 2012

ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial

Oct. 3, 2012

SBIR grant supports Colby Pharmaceutical's work in prostate cancer

Oct. 3, 2012

GTx sells Fareston

Oct. 3, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...